Andrew A. Wolff

4.2k total citations
73 papers, 2.8k citations indexed

About

Andrew A. Wolff is a scholar working on Cardiology and Cardiovascular Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Andrew A. Wolff has authored 73 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cardiology and Cardiovascular Medicine, 19 papers in Neurology and 16 papers in Molecular Biology. Recurrent topics in Andrew A. Wolff's work include Cardiac electrophysiology and arrhythmias (18 papers), Amyotrophic Lateral Sclerosis Research (17 papers) and Neurogenetic and Muscular Disorders Research (15 papers). Andrew A. Wolff is often cited by papers focused on Cardiac electrophysiology and arrhythmias (18 papers), Amyotrophic Lateral Sclerosis Research (17 papers) and Neurogenetic and Muscular Disorders Research (15 papers). Andrew A. Wolff collaborates with scholars based in United States, Canada and United Kingdom. Andrew A. Wolff's co-authors include Roberto Levi, James G. McCormack, William C. Stanley, Rick L. Barr, Gary D. Lopaschuk, Fady I. Malik, Sandra Skettino, John O. Parker, Peter C. Hanley and Bernard Chaitman and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

Andrew A. Wolff

70 papers receiving 2.7k citations

Peers

Andrew A. Wolff
Takayuki Ito Japan
Terushige Toyooka Japan
Heinz‐Gerd Zimmer Germany
Travis W. Hein United States
Kai Hu Germany
Victor G. Sharov United States
Kirill V. Tarasov United States
Lei Cui China
Yasushi Mukai Japan
M. Paul Germany
Takayuki Ito Japan
Andrew A. Wolff
Citations per year, relative to Andrew A. Wolff Andrew A. Wolff (= 1×) peers Takayuki Ito

Countries citing papers authored by Andrew A. Wolff

Since Specialization
Citations

This map shows the geographic impact of Andrew A. Wolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew A. Wolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew A. Wolff more than expected).

Fields of papers citing papers by Andrew A. Wolff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew A. Wolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew A. Wolff. The network helps show where Andrew A. Wolff may publish in the future.

Co-authorship network of co-authors of Andrew A. Wolff

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew A. Wolff. A scholar is included among the top collaborators of Andrew A. Wolff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew A. Wolff. Andrew A. Wolff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rudnicki, Stacy A., Stuart Kupfer, Fady I. Malik, et al.. (2025). Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 26(7-8). 812–820.
2.
Shefner, Jeremy M., Stuart Kupfer, Fady I. Malik, et al.. (2023). Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 25(1-2). 162–169.
3.
Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2023). Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. Journal of Medical Economics. 26(1). 488–493. 2 indexed citations
4.
Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2022). MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(3-4). 304–310. 3 indexed citations
5.
Wolff, Andrew A., et al.. (2022). In situ probe and inhibitory RNA synthesis using streamlined gene cloning with Gibson assembly. STAR Protocols. 3(3). 101458–101458. 2 indexed citations
6.
Meng, Lisa, Stacy A. Rudnicki, Noah Lechtzin, et al.. (2019). Correlation between Slow Vital Capacity Measured in the Home and in the Clinic for Patients with Amyotrophic Lateral Sclerosis (P4.4-002). Neurology. 92(15_supplement). 2 indexed citations
7.
Cary, Gregory A., et al.. (2019). Analysis of sea star larval regeneration reveals conserved processes of whole-body regeneration across the metazoa. BMC Biology. 17(1). 16–16. 47 indexed citations
8.
Teerlink, John R., G. Michael Felker, John J.V. McMurray, et al.. (2016). Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. Journal of the American College of Cardiology. 67(12). 1444–1455. 155 indexed citations
9.
Zhang, Mei, Anna Tsimelzon, Cheng Fan, et al.. (2015). Intratumoral Heterogeneity in a Trp53 -Null Mouse Model of Human Breast Cancer. Cancer Discovery. 5(5). 520–533. 54 indexed citations
10.
Greenberg, Barry, Willis Chou, Khalil G. Saikali, et al.. (2014). Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina. JACC Heart Failure. 3(1). 22–29. 53 indexed citations
11.
Shefner, Jeremy M., Andrew A. Wolff, & Lisa Meng. (2013). The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 14(7-8). 582–585. 12 indexed citations
12.
Shefner, Jeremy M., et al.. (2013). A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 14(7-8). 574–581. 27 indexed citations
13.
O’Connor, Owen A., André Goy, Robert Orlowski, et al.. (2008). A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. Journal of Clinical Oncology. 26(15_suppl). 8539–8539. 3 indexed citations
14.
Prystowsky, Eric N., Imran Khan Niazi, Anne B. Curtis, et al.. (2003). Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510),a novel A1-adenosine receptor agonist. Journal of the American College of Cardiology. 42(6). 1098–1102. 28 indexed citations
15.
Wolff, Andrew A., et al.. (1999). A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. The American Journal of Cardiology. 84(1). 46–50. 128 indexed citations
16.
Bosner, Matthew S., Andrew A. Wolff, & Richard E. Ostlund. (1999). Lack of Effect of Cholesterol Esterase Inhibitor CVT-1 on Cholesterol Absorption and LDL cholesterol in Humans. Cardiovascular Drugs and Therapy. 13(5). 449–454. 7 indexed citations
17.
Kolkman, J. J., Tao Tan, M. Oudkerk Pool, et al.. (1997). Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 11(6). 1123–1129. 7 indexed citations
18.
19.
Nicholson, Andrew, Orli R. Etingin, Kenneth B. Pomerantz, et al.. (1992). Dihydropyridine calcium antagonist modulates cholesterol metabolism and eicosanoid biosynthesis in vascular cells. Journal of Cellular Biochemistry. 48(4). 393–400. 6 indexed citations
20.
Wolff, Andrew A. & Roberto Levi. (1988). Ventricular arrhythmias parallel cardiac histamine efflux after coronary artery occlusion in the dog. Inflammation Research. 25(3-4). 296–306. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takayuki Ito Breakdown of academic impact, for papers by Terushige Toyooka Breakdown of academic impact, for papers by Heinz‐Gerd Zimmer Breakdown of academic impact, for papers by Travis W. Hein Breakdown of academic impact, for papers by Kai Hu Breakdown of academic impact, for papers by Victor G. Sharov Breakdown of academic impact, for papers by Kirill V. Tarasov Breakdown of academic impact, for papers by Lei Cui Breakdown of academic impact, for papers by Yasushi Mukai Breakdown of academic impact, for papers by M. Paul
Rankless by CCL
2026